Daily Stock Analysis, AVEO, Aveo Pharmaceuticals Inc, priceseries

Aveo Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.28
Close
2.40
High
2.41
Low
2.22
Previous Close
2.30
Daily Price Gain
0.10
YTD High
3.29
YTD High Date
Jan 31, 2018
YTD Low
1.91
YTD Low Date
Apr 6, 2018
YTD Price Change
-0.34
YTD Gain
-12.41%
52 Week High
4.24
52 Week High Date
Aug 28, 2017
52 Week Low
1.05
52 Week Low Date
Jun 23, 2017
52 Week Price Change
1.15
52 Week Gain
92.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 22. 2017
0.73
Jul 17. 2017
2.50
16 Trading Days
242.41%
Link
Company Information
Stock Symbol
AVEO
Exchange
NasdaqCM
Company URL
http://www.aveooncology.com
Company Phone
617- 531-2130
CEO
Michael P. Bailey
Headquarters
Massachusetts
Business Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001325879
About

AVEO Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the advancement of therapeutics for oncology and other areas of unmet medical need. Its products include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. It focuses on the development of its lead candidate, Tivozanib, in North America as a treatment for renal cell carcinoma and other cancers. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.